Alliance A021501 is a phase 2 randomized clinical trial that compares the efficacy of neoadjuvant modified FOLFIRINOX with or without hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas.1 The trial was led by the Alliance for Clinical Trials in Oncology with participation from the SWOG Cancer Research Network, NRG Oncology, and Eastern Cooperative Oncology Group (ECOG)–American College of Radiology Imaging Network institutions.1 The trial was conducted to establish a reference neoadjuvant regimen for borderline resectable pancreatic cancer against which to evaluate novel preoperative regimens in future clinical trials.2

The Alliance A021501 study found that patients with borderline resectable adenocarcinoma of the pancreas who were treated with chemotherapy alone before surgery lived longer than patients treated with chemotherapy followed by radiation therapy. The study also found that the most common serious side effects included diarrhea, hypokalemia (low potassium), and low white blood cell count.

1 JAMA Oncology 

2 ASCO Post

What is Alliance A021501?
Tagged on: